### Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

#### REGENERON PHARMACEUTICALS INC

Form 4

December 17, 2013

December 1	1, 2015											
FORM	FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION								OMB APPROVAL			
	UNITED		shington			NGE CC		OMB Number:	3235-0287			
Check this box if no longer									Expires:	January 31, 2005		
subject t	MENT OF	F CHANGES IN BENEFICIAL OWN SECURITIES					ERSHIP OF	Estimated a	verage			
Section 16. Form 4 or				BECCI	WIILS				burden hou response	rs per 0.5		
Form 5 obligation	^						_	Act of 1934, 1935 or Section	·			
may con See Inst	itinue.	` '		inity 1101	_				L			
1(b).	luction				•	•						
(Print or Type	Responses)											
D 111 D .				r Name <b>an</b> e	d Ticker or	Tradir	-0	5. Relationship of Reporting Person(s) to Issuer				
Powchik Peter Symbol				NERON				Tooucl				
				MACEUT	TICALS I	NC		(Check all applicable)				
		[REGN]					Director 10% Owner X Officer (give title Other (specify					
				f Earliest Transaction Day/Year)				below) below)  SVP Clinical Development & Reg				
777 OLD S ROAD	SAW MILL RIVE	ER	12/13/2	-				SVP Clinical	Development	& Reg		
	(Street)			endment, D	_	l		6. Individual or Joi	int/Group Filin	g(Check		
			Filed(Mo	nth/Day/Yea	r)			Applicable Line) _X_ Form filed by O				
TARRYTC	OWN, NY 10591						Ī	Form filed by M Person	ore than One Re	porting		
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Secur	ities Acqui	ired, Disposed of,	or Beneficial	ly Owned		
1.Title of	2. Transaction Date		1 \						6.	7. Nature of		
Security (Instr. 3)	(Month/Day/Year)	Execution any	Date, 11	Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)				Securities Beneficially	Form: H Direct (D) (	Indirect Beneficial Ownership (Instr. 4)		
		(Month/Da	ay/Year)					Owned Following				
						(A)		Reported Transaction(s)	(I) (Instr. 4)			
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)	(msu. +)			
Common Stock	12/16/2013			M(1)	8,000	A		28,742	D			
Common Stock	12/16/2013			F(1)	1,526	D	\$ 272.73	27,216	D			
Common Stock	12/16/2013			F(1)	3,338	D	\$ 272.73	23,878	D			
Common Stock	12/16/2013			M <u>(1)</u>	14,625	A	\$ 179.13	38,503	D			

 $F^{(1)}$ 

9,605

D

28,898

D

12/16/2013

### Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Common Stock					\$ 272.73			
Common Stock	12/16/2013	F(1)	2,588	D	\$ 272.73	26,310	D	
Common Stock	12/16/2013	M <u>(1)</u>	8,000	A	\$ 30.63	34,310	D	
Common Stock	12/16/2013	F(1)	898	D	\$ 272.73	33,412	D	
Common Stock	12/16/2013	F(1)	3,662	D	\$ 272.73	29,750	D	
Common Stock	12/17/2013	S(1)	8	D	\$ 270	29,742	D	
Common Stock						1,589	I	By 401(k) Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities Acquired (Instr. 8) (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and 2 Underlying S (Instr. 3 and	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
Non-Qualified Stock Option (right to buy)	\$ 30.63	12/13/2013		A	48,000		(2)	12/14/2020	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 30.63	12/16/2013		M <u>(1)</u>		8,000	<u>(3)</u>	12/14/2020	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 52.03	12/16/2013		M <u>(1)</u>		8,000	(3)	12/16/2021	Common Stock
Non-Qualified Stock Option (right to buy)	\$ 179.13	12/16/2013		M <u>(1)</u>		14,625	<u>(4)</u>	12/14/2022	Common Stock

#### Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Non-Qualified

(right to buy)

Stock Option \$ 270.43 1

12/13/2013

A 40,000

(4) 12/13/2023

Common Stock

# **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Powchik Peter SVP Clinical
777 OLD SAW MILL RIVER ROAD Development &
TARRYTOWN, NY 10591 Reg

**Signatures** 

/s/\*\*Peter Powchik 12/17/2013

\*\*Signature of Date
Reporting Person

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- On December 14, 2010, the reporting person was granted an option to purchase 48,000 shares of Common Stock. The option vests, partially or in full, on December 31, 2013, based on the extent to which the company satisfies certain performance criteria during the
- period ending December 31, 2013. The performance criteria have been met and the option will vest as to all 48,000 shares on December 31, 2013.
- (3) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
- (4) The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3